van Zuylen L - Search Results

1

Potentially inappropriate end-of-life care and its association with relatives' well-being: a systematic review.

Ham L, Slotman E, Burghout C, Raijmakers NJ, van de Poll-Franse LV, van Zuylen L, Fransen HP. Ham L, et al. Among authors: van zuylen l, van de poll franse lv. Support Care Cancer. 2023 Nov 30;31(12):731. doi: 10.1007/s00520-023-08198-0. Support Care Cancer. 2023. PMID: 38055062 Review.

2

Medicinal cannabis in oncology practice: still a bridge too far?

de Jong FA, Engels FK, Mathijssen RH, van Zuylen L, Verweij J, Peters RP, Sparreboom A. de Jong FA, et al. Among authors: van zuylen l. J Clin Oncol. 2005 May 1;23(13):2886-91. doi: 10.1200/JCO.2005.04.150. J Clin Oncol. 2005. PMID: 15860846 No abstract available.

3

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.

van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A. van Zuylen L, et al. Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18. doi: 10.1007/s002800000215. Cancer Chemother Pharmacol. 2001. PMID: 11345647 Clinical Trial.

4

Consultation in palliative care: the relevance of clarification of problems.

Vernooij-Dassen MJ, Groot MM, van den Berg J, Kuin A, van der Linden BA, van Zuylen L, Crul BJ, Grol RP. Vernooij-Dassen MJ, et al. Among authors: van den berg j, van zuylen l, van der linden ba. Eur J Cancer. 2007 Jan;43(2):316-22. doi: 10.1016/j.ejca.2006.10.003. Epub 2006 Nov 17. Eur J Cancer. 2007. PMID: 17113281

5

Continuous palliative sedation: not only a response to physical suffering.

Swart SJ, van der Heide A, van Zuylen L, Perez RS, Zuurmond WW, van der Maas PJ, van Delden JJ, Rietjens JA. Swart SJ, et al. Among authors: van delden jj, van der heide a, van zuylen l, van der maas pj. J Palliat Med. 2014 Jan;17(1):27-36. doi: 10.1089/jpm.2013.0121. J Palliat Med. 2014. PMID: 24410419

6

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.

van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Sparreboom A. van Zuylen L, et al. Anticancer Drugs. 2000 Jun;11(5):331-7. doi: 10.1097/00001813-200006000-00003. Anticancer Drugs. 2000. PMID: 10912949 Clinical Trial.

7

Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.

van Zuylen L, Schellens JH, Goey SH, Pronk LC, de Boer-Dennert MM, Loos WJ, Ma J, Stoter G, Verweij J. van Zuylen L, et al. Anticancer Drugs. 1999 Apr;10(4):361-8. doi: 10.1097/00001813-199904000-00003. Anticancer Drugs. 1999. PMID: 10378670 Clinical Trial.

8

Audit of the Liverpool Care Pathway for the Dying Patient in a Dutch cancer hospital.

Veerbeek L, van Zuylen L, Gambles M, Swart SJ, van der Heide A, van der Rijt CC, Ellershaw JE. Veerbeek L, et al. Among authors: van der heide a, van der rijt cc, van zuylen l. J Palliat Care. 2006 Winter;22(4):305-8. J Palliat Care. 2006. PMID: 17263060 No abstract available.

9

A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy.

Geijteman ECT, Wensveen CWM, Duvekot JJ, van Zuylen L. Geijteman ECT, et al. Among authors: van zuylen l. Obstet Gynecol. 2014 Aug;124(2 Pt 2 Suppl 1):454-456. doi: 10.1097/AOG.0000000000000389. Obstet Gynecol. 2014. PMID: 25004323

10

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J. van Zuylen L, et al. Among authors: van der gaast a. Eur J Cancer. 2002 May;38(8):1090-9. doi: 10.1016/s0959-8049(02)00035-7. Eur J Cancer. 2002. PMID: 12008197

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

121 results

Search Page